Volltextsuche nach »nordisk«

Branchenbuchsuche nach »nordisk«

Keyword-Suche nach »nordisk«, Treffer 1 bis 24 von 24

1.) Novo Nordisk A/S, Share repurchase programme

[…] Nordisk A/S, Share repurchase programme Bagsværd, Denmark, 10 January 2022On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period […] weiterlesen …

2.) Novo Nordisk A/S, Share repurchase programme

[…] Nordisk A/S, Share repurchase programme Bagsværd, Denmark, 17 January 2022On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period […] weiterlesen …

3.) Financial report for the period 1 January 2021 to 31 December 2021

[…] report for the period 1 January 2021 to 31 December 2021 Operating profit increased by 8% in Danish kroner and by 13% at constant exchange rates (CER) to DKK 58. 6 billion. Sales in International Operations increased by 12% in Danish kroner (14% at CER), and sales in North America Operations increased by 10% in Danish kroner (14% at CER). Sales within Diabetes and Obesity care increased by 13% in Danish kroner to DKK 121. 6 billion (15% at CER), driven by GLP-1 sales growth of 28% in Danish […] weiterlesen …

4.) Novo Nordisk files annual report with the SEC

[…] Nordisk files annual report with the SEC Bagsværd, Denmark, 2 February 2022Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021. The reports are available at the SEC's website, www. sec. gov, as well as on novonordisk. com. Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free […] weiterlesen …

5.) Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

[…] Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 4 February 2022This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. Members of Executive Management have participated in a long-term incentive programme consisting of a one-year […] weiterlesen …

6.) Novo Nordisk – major shareholder announcement

[…] Nordisk – major shareholder announcement Bagsværd, Denmark, 14 February 2022Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5. 05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to […] weiterlesen …

7.) Novo Nordisk A/S: Share repurchase programme

[…] Nordisk A/S: Share repurchase programme Bagsværd, Denmark, 21 February 2022On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 22 billion to be executed during a 12-month period […] weiterlesen …

8.) Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines

[…] Nordisk expands research collaboration in novel delivery technologies for biologic medicines Bagsværd, Denmark, 9 March 2022Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH). Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives […] weiterlesen …

9.) Novo Nordisk – major shareholder announcement

[…] Nordisk – major shareholder announcement Bagsværd, Denmark, 14 March 2022Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section […] weiterlesen …

10.) Heavy bleeding after giving birth is globally a leading cause of death in new mothers

[…] bleeding after giving birth is globally a leading cause of death in new mothers [1] Bagsværd, Denmark, 22 April 2022Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding […] weiterlesen …

11.) Novo Nordisk A/S, Share Repurchase Programme

[…] Novo Nordisk A/S, Share Repurchase Programme Bagsværd, Denmark, 16 May 2022On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period […] weiterlesen …

12.) Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials

[…] Nordisk achieves primary objectives of Onwards 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in Onwards 1 Bagsværd, Denmark, 3 June 2022Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. Onwards 1 (insulin naïve people with type 2 diabetes) Onwards 1 is a phase 3a, 78-week efficacy and safety treat-to-target trial […] weiterlesen …

13.) Novo Nordisk—major shareholder announcement

[…] Novo Nordisk—major shareholder announcement Bagsværd, Denmark, 7 June 2022Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to […] weiterlesen …

14.) Neuer Wirkstoff-Kandidat für die Behandlung des Typ 2 Diabetes entwickelt

[…] Wirkstoff-Kandidat für die Behandlung des Typ 2 Diabetes entwickelt Forscher von Helmholtz Munich, dem Deutschen Zentrum für Diabetesforschung (DZD) und Novo Nordisk haben eine neue Hormon Kombination für die künftige Behandlung des Typ 2 Diabetes entwickelt. Die Wissenschaftler haben die blutzuckersenkenden Effekte des Medikaments Tesaglitazar und des Hormons GLP 1 in einem neuen hochwirksamen Wirkstoff verbunden. Durch die Kombination mit GLP 1 gelangt das neue Molekül nur in Gewebe, das […] weiterlesen …

15.) Once-weekly insulin icodec demonstrates superior reduction in HbA1c

[…] insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in Onwards 5 phase 3a trial Bagsværd, Denmark, 3rd October 2022Novo Nordisk today announced headline results from the Onwards 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The Onwards 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus […] weiterlesen …

16.) Novo Nordisk A/S, Share repurchase programme

[…] Nordisk A/S, Share repurchase programme Bagsværd, Denmark, November 4th, 2022The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3. 8 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe […] weiterlesen …

17.) Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

[…] Nordisk invests DKK 5. 4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark Bagsværd, Denmark, November 22nd, 2022Novo Nordisk today announced plans to invest 5. 4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R & D for manufacturing of active pharmaceutical ingredients […] weiterlesen …

18.) Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure

[…] and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan, Bagsværd, Denmark, February 10th, 2023Heartseed Inc. (Heartseed) and Novo Nordisk […] weiterlesen …

19.) Novo Nordisk to Expand R & D Presence in Greater Boston Area

[…] Nordisk to Expand R & D Presence in Greater Boston Area Bagsværd, Denmark, March 2nd, 2023Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development […] weiterlesen …

20.) Job Analyse von Deutschlands Pharmariesen: Diese Top Pharmaunternehmen suchen die meisten Fachkräfte und Führungskräfte

[…] Analyse von Deutschlands Pharmariesen: Diese Top Pharmaunternehmen suchen die meisten Fachkräfte und Führungskräfte Die Personalberatung ACC untersucht die Stellenangebote der 30 Top Pharmaunternehmen DeutschlandsChefs gesucht: 61,4 Prozent der ausgeschriebenen Jobs bei Hexal richten sich an FührungskräfteJanssen sucht derzeit hingegen kein FührungspersonalBerlin, 2. März 2023In Deutschlands Pharmaunternehmen sind Führungskräfte heiß begehrt: 500 von 3508 ausgeschriebenen Stellen […] weiterlesen …

21.) Deutscher Filmpreis 2023: Lola in Gold und Bronze sowie 7 weitere für Arte Coproduktionen

[…] Filmpreis 2023: Lola in Gold und Bronze sowie 7 weitere für Arte Coproduktionen Strasbourg, 14. Mai 2023Am Freitagabend fand im Theater am Potsdamer Platz in Berlin die Verleihung des Deutschen Filmpreis 2023 statt. Arte freut sich über insgesamt neun Auszeichnungen, darunter alleine fünf für die Arte Coproduktion »Das Lehrerzimmer« von Ilker Çatak, die auch die Lola in Gold als Besten Spielfilm erhielt. Die Arte Coproduktion »Holy Spider« von Ali Abbasi wurde mit der Lola in Bronze […] weiterlesen …

22.) Amazon Sverige bekræfter deltagelse i amaNordic

[…] Sverige bekræfter deltagelse i amaNordic Amazon Sveriges ledelse har meddelt, at de vil deltage i amaNordic i Gummifabriken, Värnamo. Som den eneste etablerede begivenhed i Norden dedikeret til Amazon-sælgere, fremstår amaNordic som det oplagte valg for alle, der er seriøse omkring deres Amazon-rejse. Denne deltagelse understreger Amazons engagement i at styrke båndene til nordiske brands og giver en unik mulighed for deltagerne at interagere direkte med Amazons repræsentanter, opbygge […] weiterlesen …

23.) Stefan Kühn: Der Ozempic Hype! Das Diabetes Medikament Ozempic macht als Schlankheitsmittel Furore

[…] Kühn: Der Ozempic Hype! Das Diabetes Medikament Ozempic macht als Schlankheitsmittel FuroreSK Consulting , Köln, 17. Dezember 2023Stefan Kühn, Betriebswirt und Ökonom, beleuchtet den Ozempic Hype: »Das Diabetes Medikament Ozempic hat nicht nur einen wichtigen Durchbruch in der Behandlung von Diabetikern erzielt«. Es erweist sich auch als wegweisende Lösung im Bereich des Gewichtsmanagements. Die jüngsten Entwicklungen haben zu einem auffälligen Phänomen geführt: dem so genannten […] weiterlesen …

24.) »ApoRisk«: Apotheken Nachrichten vom 18. Dezember 2023 – Update

[…] Nachrichten vom 18. Dezember 2023 – Update»Entdecken Sie die dynamische Entwicklung, wegweisende Forschung und die bedeutendsten Herausforderungen, die die Apothekenlandschaft prägen« Karlsruhe, 18. Dezember 2023»Willkommen zu den Apotheken Nachrichten! Hier halten wir Sie über die neuesten Entwicklungen im Apothekenwesen auf dem Laufenden. Von gesetzlichen Änderungen über innovative Apothekenkonzepte bis hin zu Fortschritten in der Arzneimittelforschung – wir bringen Ihnen relevante […] weiterlesen …